J Pathol Transl Med.  2019 May;53(3):173-179. 10.4132/jptm.2019.02.03.

Prognostic Role of Claudin-1 Immunohistochemistry in Malignant Solid Tumors: A Meta-Analysis

• Pyo JS
• Kim NY
• Cho WJ

• KMID: 2449340
• DOI: http://doi.org/10.4132/jptm.2019.02.03

Abstract

BACKGROUND
Although the correlation between low claudin-1 expression and worse prognosis has been reported, details on the prognostic implications of claudin-1 expression in various malignant tumors remain unclear. The present study aimed to elucidate the prognostic roles of claudin- 1 immunohistochemistry (IHC) in various malignant tumors through a meta-analysis.
METHODS
The study included 2,792 patients from 22 eligible studies for assessment of the correlation between claudin-1 expression and survival rate in various malignant tumors. A subgroup analysis based on the specific tumor and evaluation criteria of claudin-1 IHC was conducted.
RESULTS
Low claudin-1 expression was significantly correlated with worse overall survival (OS) (hazard ratio [HR], 1.851; 95% confidence interval [CI], 1.506 to 2.274) and disease-free survival (DFS) (HR, 2.028; 95% CI, 1.313 to 3.134) compared to high claudin-1 expression. Breast, colorectal, esophageal, gallbladder, head and neck, and lung cancers, but not cervical, liver or stomach cancers, were significantly correlated with worse OS. Breast, colorectal, esophageal, and thyroid cancers with low claudin-1 expression were associated with poorer DFS. In the lower cut-off subgroup (< 25.0%) with respect to claudin-1 IHC, low claudin-1 expression was significantly correlated with worse OS and DFS.
CONCLUSIONS
Taken together, low claudin-1 IHC expression is significantly correlated with worse survival in various malignant tumors. More detailed criteria for claudin-1 IHC expression in various malignant tumors are needed for application in daily practice.

Keyword

Claudin-1; Immunohistochemistry; Prognosis; Malignancy; Meta-analysis

MeSH Terms

Breast
Claudin-1*
Disease-Free Survival
Gallbladder
Head
Humans
Immunohistochemistry*
Liver
Lung Neoplasms
Neck
Prognosis
Stomach Neoplasms
Survival Rate
Thyroid Neoplasms
Claudin-1

Figure

• 

  Fig. 1. Flow chart for study search and selection methods.

• 

  Fig. 2. Forest plot diagram showing the correlation between low claudin-1 immunohistochemical expression and overall survival (A) and disease-free survival (B)[9,11-31]. CI, confidence interval.

• 

  Fig. 3. Forest plot diagram for subgroup analysis based on cut-off value of low claudin-1 immunohistochemical expression. OS, overall survival; DFS, disease-free survival.

Reference

1. Colegio OR, Van Itallie C, Rahner C, Anderson JM. Claudin extracellular domains determine paracellular charge selectivity and resistance but not tight junction fibril architecture. Am J Physiol Cell Physiol. 2003; 284:C1346–54.

2. Miwa N, Furuse M, Tsukita S, Niikawa N, Nakamura Y, Furukawa Y. Involvement of claudin-1 in the beta-catenin/Tcf signaling pathway and its frequent upregulation in human colorectal cancers. Oncol Res. 2001; 12:469–76.

3. Bhat AA, Sharma A, Pope J, et al. Caudal homeobox protein Cdx-2 cooperates with Wnt pathway to regulate claudin-1 expression in colon cancer cells. PLoS One. 2012; 7:e37174.

4. Tsukita S, Furuse M. The structure and function of claudins, cell adhesion molecules at tight junctions. Ann N Y Acad Sci. 2000; 915:129–35.

5. Günzel D, Fromm M. Claudins and other tight junction proteins. Compr Physiol. 2012; 2:1819–52.

6. Krug SM, Schulzke JD, Fromm M. Tight junction, selective permeability, and related diseases. Semin Cell Dev Biol. 2014; 36:166–76.

7. Koval M. Claudin heterogeneity and control of lung tight junctions. Annu Rev Physiol. 2013; 75:551–67.

8. Capaldo CT, Nusrat A. Claudin switching: physiological plasticity of the tight Junction. Semin Cell Dev Biol. 2015; 42:22–9.

9. Huang J, Li J, Qu Y, et al. The expression of claudin 1 correlates with beta-catenin and is a prognostic factor of poor outcome in gastric cancer. Int J Oncol. 2014; 44:1293–301.

10. Suh Y, Yoon CH, Kim RK, et al. Claudin-1 induces epithelial-mesenchymal transition through activation of the c-Abl-ERK signaling pathway in human liver cells. Oncogene. 2013; 32:4873–82.

11. Bouchagier KA, Assimakopoulos SF, Karavias DD, et al. Expression of claudins-1, -4, -5, -7 and occludin in hepatocellular carcinoma and their relation with classic clinicopathological features and patients’ survival. In Vivo. 2014; 28:315–26.

12. Chae MC, Park CK, Keum DY, Hwang I, Kwon KY, Jang BC. Prognostic significance of claudin 4 in completely resected adenocarcinoma of the lung. Korean J Thorac Cardiovasc Surg. 2014; 47:262–8.

13. Chao YC, Pan SH, Yang SC, et al. Claudin-1 is a metastasis suppressor and correlates with clinical outcome in lung adenocarcinoma. Am J Respir Crit Care Med. 2009; 179:123–33.

14. Fritzsche FR, Oelrich B, Johannsen M, et al. Claudin-1 protein expression is a prognostic marker of patient survival in renal cell carcinomas. Clin Cancer Res. 2008; 14:7035–42.

15. Higashi Y, Suzuki S, Sakaguchi T, et al. Loss of claudin-1 expression correlates with malignancy of hepatocellular carcinoma. J Surg Res. 2007; 139:68–76.

16. Hoellen F, Waldmann A, Banz-Jansen C, et al. Claudin-1 expression in cervical cancer. Mol Clin Oncol. 2017; 7:880–4.

17. Jung H, Jun KH, Jung JH, Chin HM, Park WB. The expression of claudin-1, claudin-2, claudin-3, and claudin-4 in gastric cancer tissue. J Surg Res. 2011; 167:e185–91.

18. Li WJ, Zhang ZL, Yu XM, Cai XL, Pan XL, Yang XY. Expression of claudin-1 and its relationship with lymphatic microvessel generation in hypopharyngeal squamous cell carcinoma. Genet Mol Res. 2015; 14:11814–26.

19. Ma F, Ding X, Fan Y, et al. A CLDN1-negative phenotype predicts poor prognosis in triple-negative breast cancer. PLoS One. 2014; 9:e112765.

20. Matsuoka T, Mitomi H, Fukui N, et al. Cluster analysis of claudin-1 and -4, E-cadherin, and beta-catenin expression in colorectal cancers. J Surg Oncol. 2011; 103:674–86.

21. Merikallio H, Kaarteenaho R, Pääkkö P, et al. Impact of smoking on the expression of claudins in lung carcinoma. Eur J Cancer. 2011; 47:620–30.

22. Miyamoto K, Kusumi T, Sato F, et al. Decreased expression of claudin-1 is correlated with recurrence status in esophageal squamous cell carcinoma. Biomed Res. 2008; 29:71–6.

23. Morohashi S, Kusumi T, Sato F, et al. Decreased expression of claudin-1 correlates with recurrence status in breast cancer. Int J Mol Med. 2007; 20:139–43.

24. Resnick MB, Konkin T, Routhier J, Sabo E, Pricolo VE. Claudin-1 is a strong prognostic indicator in stage II colonic cancer: a tissue microarray study. Mod Pathol. 2005; 18:511–8.

25. Sappayatosok K, Phattarataratip E. Overexpression of claudin-1 is associated with advanced clinical stage and invasive pathologic characteristics of oral squamous cell carcinoma. Head Neck Pathol. 2015; 9:173–80.

26. Shibutani M, Noda E, Maeda K, Nagahara H, Ohtani H, Hirakawa K. Low expression of claudin-1 and presence of poorly-differentiated tumor clusters correlate with poor prognosis in colorectal cancer. Anticancer Res. 2013; 33:3301–6.

27. Shin HI, Kim BH, Chang HS, Kim CI, Jung HR, Park CH. Expression of claudin-1 and -7 in clear cell renal cell carcinoma and its clinical significance. Korean J Urol. 2011; 52:317–22.

28. Tzelepi VN, Tsamandas AC, Vlotinou HD, Vagianos CE, Scopa CD. Tight junctions in thyroid carcinogenesis: diverse expression of claudin-1, claudin-4, claudin-7 and occludin in thyroid neoplasms. Mod Pathol. 2008; 21:22–30.

29. Xiong L, Wen Y, Miao X, Yang Z. Expressions of cell junction regulatory proteins and their association with clinicopathologic parameters in benign and malignant gallbladder lesions. Am J Med Sci. 2011; 342:388–94.

30. Yoshida T, Kinugasa T, Akagi Y, et al. Decreased expression of claudin-1 in rectal cancer: a factor for recurrence and poor prognosis. Anticancer Res. 2011; 31:2517–25.

31. Zhang Z, Wang A, Sun B, Zhan Z, Chen K, Wang C. Expression of CLDN1 and CLDN10 in lung adenocarcinoma in situ and invasive lepidic predominant adenocarcinoma. J Cardiothorac Surg. 2013; 8:95.

32. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998; 17:2815–34.

33. Mineta K, Yamamoto Y, Yamazaki Y, et al. Predicted expansion of the claudin multigene family. FEBS Lett. 2011; 585:606–12.

34. Singh AB, Sharma A, Dhawan P. Claudin-1 expression confers resistance to anoikis in colon cancer cells in a Src-dependent manner. Carcinogenesis. 2012; 33:2538–47.

35. Kinugasa T, Akagi Y, Ochi T, et al. Increased claudin-1 protein expression in hepatic metastatic lesions of colorectal cancer. Anticancer Res. 2012; 32:2309–14.

36. Chang TL, Ito K, Ko TK, et al. Claudin-1 has tumor suppressive activity and is a direct target of RUNX3 in gastric epithelial cells. Gastroenterology. 2012; 138:255–65.e1-3.